Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer

Cytokine-induced killer (CIK) cell therapy is a type of adoptive immunotherapy that due to its high proliferation rate and anti-tumor characteristics, is being investigated to treat various solid tumors. Since advanced colorectal cancer (CRC) has high mortality and poor survival rates, and the effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Fayyaz, Farimah, Yazdanpanah, Niloufar, Rezaei, Nima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962105/
https://www.ncbi.nlm.nih.gov/pubmed/35346234
http://dx.doi.org/10.1186/s12964-022-00836-0
_version_ 1784677726707253248
author Fayyaz, Farimah
Yazdanpanah, Niloufar
Rezaei, Nima
author_facet Fayyaz, Farimah
Yazdanpanah, Niloufar
Rezaei, Nima
author_sort Fayyaz, Farimah
collection PubMed
description Cytokine-induced killer (CIK) cell therapy is a type of adoptive immunotherapy that due to its high proliferation rate and anti-tumor characteristics, is being investigated to treat various solid tumors. Since advanced colorectal cancer (CRC) has high mortality and poor survival rates, and the efficacy of chemotherapy and radiotherapy is limited in treatment, the application of CIK cell therapy in CRC has been evaluated in numerous studies. This review aims to summarize the clinical studies that investigated the safety and clinical efficacy of CIK cell therapy in CRC. Therefore, 1,969 enrolled CRC patients in the clinical trials, of which 842 patients received CIK cells in combination with chemotherapy with or without dendritic cell (DC) infusions, were included in the present review. Furthermore, the signaling pathways involved in CIK cell therapy and novel methods for improving migration abilities are discussed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-022-00836-0.
format Online
Article
Text
id pubmed-8962105
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89621052022-03-30 Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer Fayyaz, Farimah Yazdanpanah, Niloufar Rezaei, Nima Cell Commun Signal Review Cytokine-induced killer (CIK) cell therapy is a type of adoptive immunotherapy that due to its high proliferation rate and anti-tumor characteristics, is being investigated to treat various solid tumors. Since advanced colorectal cancer (CRC) has high mortality and poor survival rates, and the efficacy of chemotherapy and radiotherapy is limited in treatment, the application of CIK cell therapy in CRC has been evaluated in numerous studies. This review aims to summarize the clinical studies that investigated the safety and clinical efficacy of CIK cell therapy in CRC. Therefore, 1,969 enrolled CRC patients in the clinical trials, of which 842 patients received CIK cells in combination with chemotherapy with or without dendritic cell (DC) infusions, were included in the present review. Furthermore, the signaling pathways involved in CIK cell therapy and novel methods for improving migration abilities are discussed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-022-00836-0. BioMed Central 2022-03-28 /pmc/articles/PMC8962105/ /pubmed/35346234 http://dx.doi.org/10.1186/s12964-022-00836-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Fayyaz, Farimah
Yazdanpanah, Niloufar
Rezaei, Nima
Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer
title Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer
title_full Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer
title_fullStr Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer
title_full_unstemmed Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer
title_short Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer
title_sort cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962105/
https://www.ncbi.nlm.nih.gov/pubmed/35346234
http://dx.doi.org/10.1186/s12964-022-00836-0
work_keys_str_mv AT fayyazfarimah cytokineinducedkillercellsmediatedpathwaysinthetreatmentofcolorectalcancer
AT yazdanpanahniloufar cytokineinducedkillercellsmediatedpathwaysinthetreatmentofcolorectalcancer
AT rezaeinima cytokineinducedkillercellsmediatedpathwaysinthetreatmentofcolorectalcancer

Ejemplares similares